---
schema_version: "secwatch.filing_event.v1"
accession: "0001125345-24-000061"
form_type: "8-K"
ticker: "MGNX"
cik: "0001125345"
company_name: "MACROGENICS INC"
filed_at: "2024-03-07T23:59:59+00:00"
generated_at: "2026-06-05T01:08:39.931408+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MacroGenics reports FY2023 net loss of $9.1M; cash $229.8M; vobra duo data at ASCO 2024

## Summary
- Net loss $9.1M vs $119.8M in 2022; revenue $58.7M (down 61% YoY) due to lower collaboration revenue.
- Cash, equivalents & securities $229.8M as of Dec 31, 2023, up from $154.3M; cash runway into 2026.
- Preliminary TAMARACK Phase 2 data for vobra duo in mCRPC expected at ASCO 2024; 177 patients enrolled.
- Initiated Phase 1 dose escalation of MGC026 (topoisomerase I inhibitor-based ADC) in advanced solid tumors.
- Received $100M from sale of TZIELD royalty interest and $50M milestone from Sanofi, recorded as $150.9M gain.

## SEC filing metadata
- accession: 0001125345-24-000061
- form_type: 8-K
- ticker: MGNX
- cik: 0001125345
- company_name: MACROGENICS INC
- filed_at: 2024-03-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1125345/000112534524000061/0001125345-24-000061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1125345/000112534524000061/mgnx-20240307.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001125345-24-000061
- JSON: https://secwatch.observer/filing/0001125345-24-000061.json
- Plain text: https://secwatch.observer/filing/0001125345-24-000061.txt

## Key facts
- Earnings Releases
  MACROGENICS INC reported financial results for the year ended December 31, 2023.
  - Period: the year ended December 31, 2023
  - Result: reported results
  source text: On March 7, 2024, MacroGenics, Inc. (the "Company") announced financial and operating results as of and for the year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1125345/000112534524000061/0001125345-24-000061-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.